Drawing upon the findings from the SOLAR-1 study, the U.S. FDA has granted approval for alpelisib, a PI3K inhibitor, for the treatment of HR+/HER2- advanced breast cancer in patients harboring PIK3CA mutations (92). This evidence concerns the gene PIK3CA and breast cancer.